Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by mining4dollarson May 10, 2013 9:47am
163 Views
Post# 21362352

RE: RE: RE: RE: RE: RE: RE: I hope......

RE: RE: RE: RE: RE: RE: RE: I hope......

JD, I most certainly agree with you on that; the timing of this is suspect given the fact they have announced, and reaffirmend that they plan to release further Interim Phase 2 data by the end of Q2(which is a matter of weeks).

I do see that being a major catalyst for us, given the fact that 007 is why we are all here in the first place, and hopefully if enough people voice their displeasure with management over the current state of affairs perhaps they can be urged to include efficacy.  With the trial as advanced as it is at this point, there should be an abundance of information they COULD share(which could potentially catapult us if in line with phase 1 stuff), it is now a question of "will they".

 

Bullboard Posts